Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONALAAPG · Entity 4672 | Chief Financial Officer | April 20, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASCENTAGE PHARMA GROUP INTERNATIONAL
Report date April 20, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock unitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 18,584 |
Reported balance
After 2026-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 18,584 · Balance 18,584 F1: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest immediately and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest immediately and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 20, 2026 Filed Apr 21, 2026 17:37 UTC | ASCENTAGE PHARMA GROUP INTERNATIONAL AAPG · Entity 4672 | GrantRestricted stock units · Derivative | 18,584 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-046036 · marketforms-72968.xml · derivative · entry 1 Misra Veet · CIK 0002122967 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,584 Underlying: Restricted stock units · 18,584 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest immediately and have no expiration date. F1 · derivative.expiration_date: Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest immediately and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.